ADDS Cognitive Impairment Screening System

Product type: Class II medical devices

Product Registration Certificate Number: Jixie Zhuzhun 20232070196

Product registration name: Cognitive Impairment Screening Device

1. Brain nerve signal acquisitionThe subjects wear non-invasive sensors to collect real-time electroencephalogram (EEG) signals;

   
   

2. Cognitive task triggeringGuide the completion of standardized cognitive tasks (such as memory, attention, and executive function tests);

   
   

3. AI feature extractionThrough independently developed AI algorithms, quickly analyze multidimensional cognitive features in brain signals;

   
   

4. Quantitative report generationCombining scales such as MMSE and MoCA with EEG features, output within 15 minutesvisualizationThe cognitive function assessment report should clarify whether there is early cognitive impairment.

   
   

1. Safe and user-friendly experience

• Non invasive brain computer interface technology, non-invasive, subjects only need to wear lightweight sensors, and there is no pain throughout the process;

  
  

• The cognitive task design is suitable for daily scenarios, easy to operate, and easy for the elderly/high-risk groups to cooperate.

  
  

2. Fast and efficient, with quantified results

• Single case screening only requires15 minutesSupport batch processing and adapt to scenarios such as large-scale initial screening in communities and rapid evaluation in hospital outpatient clinics;

  
  

• The report includesMultidimensional cognitive score+EEG+risk level assessmentReject vague descriptions and provide objective basis for clinical decision-making.

  
  

3. Accurate and reliable, with advanced technologyexcellent

• Screening accuracytallCan recognize early signals of mild cognitive impairment (MCI) and Alzheimer's disease;

  
  

• Core technical indicators achievedExcellent levelObtained certification from the "China Good Technology" project library, breaking down technical barriers in the international field of neural regulation.

  
  

4. Scene adaptation, full level coverage

• Class A tertiary hospitalSupport precise diagnosis of complex cases (such as neurology, geriatrics), and assist in developing personalized intervention plans;

  
  

• Grassroots/CommunityEasy to operate, capable of conducting large-scale population screening (such as annual physical examinations for elderly people aged 60 and above);

  
  

• Elderly care institutions/health management centersEmbed routine health monitoring processes to promptly detect cognitive changes in occupants and collaborate with family members and medical teams.

  
  

Core Value

• For patientsEarly detection of cognitive impairment, seizing the "golden intervention" of Alzheimer's disease, and delaying disease progression;

  
  

• For medical institutions：supplementLack of early screening technology at the grassroots level, improving diagnosis and treatment efficiency (bidding farewell to "relying solely on experience judgment"), and supporting the implementation of graded diagnosis and treatment;

  
  

• to societyReduce the cost of late stage care for Alzheimer's disease, alleviate the burden on families and society, and help promote "healthy aging".

  
  

【 Application Scenarios 】

• Hospitals: Cognitive impairment clinics/wards in neurology, geriatrics, and psychiatry;

  
  

• Community: Annual health screening for community health service centers and elderly activity centers;

  
  

• Institution: Routine cognitive monitoring of nursing homes, nursing homes, and health management centers;

  
  

• Research: Epidemiological investigation of cognitive impairment, baseline evaluation of new drug clinical trials.

  
  

•